Yuzuru Niibe1,2, Takaya Yamamoto3, Hiroshi Onishi4, Hideomi Yamashita5, Kuniaki Katsui6, Yasuo Matsumoto7, Ryoong-Jin Oh8, Masahiko Aoki9, Takashi Shintani10, Kazunari Yamada11, Mitsuru Kobayashi12, Masatoki Ozaki13, Yoshihiko Manabe14, Katsuya Yahara15, Atsushi Nishikawa16, Hisao Kakuhara17, Kentaro Yamamoto18, Tetsuya Inoue19, Y U Takada20, Kenji Nagata21, Osamu Suzuki22, Atsuro Terahara23, Keiichi Jingu3. 1. Department of Radiology, Toho University Omori Medical Center, Tokyo, Japan joe-n@hkg.odn.ne.jp. 2. Department of Primary Care and Medical Education, Okayama University, Okayama, Japan. 3. Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. 4. Department of Radiology, University of Yamanashi, Yamanashi, Japan. 5. Department of Radiology, the University of Tokyo, Tokyo, Japan. 6. Department of Proton Beam Therapy, Okayama University, Okayama, Japan. 7. Department of Radiation Oncology, Niigata Cancer Center Hospital, Niigata, Japan. 8. Department of Radiation Oncology, Miyakojima IGRT Clinic, Osaka, Japan. 9. Department of Radiology, Hirosaki University, Hirosaki, Japan. 10. Department of Radiation Oncology and Image-applied Therapy, Kyoto University, Kyoto, Japan. 11. Department of Radiation Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan. 12. Department of Radiation Oncology, Seirei Mikatahara General Hospital, Shizuoka, Japan. 13. Deparment of Radiation Oncology, Fukuyama City Hospital, Hiroshima, Japan. 14. Department. of Radiation Oncology, Shizuoka City Shimizu Hospital, Shizuoka, Japan. 15. Department of Radiology, Nagoya City University, Nagoya, Japan. 16. Department of Radiology, University of Occupational and Environmental Health, Fukuoka, Japan. 17. Department of Radiation Oncology, Shikoku Cancer Center, Ehime, Japan. 18. Department of Radiology, Iwate Medical University, Iwate, Japan. 19. Department of Radiology, Self-Defense Forces Central Hospital, Tokyo, Japan. 20. Department of Nagasaki Prefecture Shimabara Hospital, Nagasaki, Japan. 21. Department Radiology, Hokkaido University Hospital, Sapporo, Japan. 22. Department of Radiology, Juntendo University Hospital, Tokyo, Japan. 23. Department of Radiology, Toho University Omori Medical Center, Tokyo, Japan.
Abstract
AIM: This study was performed to confirm the superior overall survival (OS) after pulmonary oligo-recurrence compared to pulmonary sync-oligometastases in a large nationwide study. PATIENTS AND METHODS: Patients that met the following criteria were included: 1 to 5 lung-only metastases at the beginning of stereotactic body radiation therapy (SBRT) was performed between January 2004 and June 2015, and the biological effective dose (BED) of SBRT was 75 Gy or more. The parameters included in the analyses were age, gender, ECOG PS, primary lesion, pathology, oligoetastatic state, SBRT date, chemotherapy before SBRT, chemotherapy concurrent SBRT, chemotherapy after SBRT, maximum tumor diameter, number of metastases, field coplanarity, dose prescription, BED10, OTT of SBRT. RESULTS: In total, 1,378 patients with 1,547 tumors were enrolled. Oligo-recurrence occurred in 1,016 patients, sync-oligometastases in 118, and unclassified oligometastases in 121. The three-year OS was 64.0% for oligo-recurrence and 47.5% for sync-oligometastasis (p<0.001). In the multivariate analysis, the hazard ratio (HR) for sync-oligometastases versus oligo-recurrence was 1.601 (p=0.014). Adverse events of Grade 5 were occurred in 3 patients. CONCLUSION: This is the first nationwide to indicate that the OS of patients with pulmonary oligo-recurrence is better than that of patients with sync-oligometastases. Copyright
AIM: This study was performed to confirm the superior overall survival (OS) after pulmonary oligo-recurrence compared to pulmonary sync-oligometastases in a large nationwide study. PATIENTS AND METHODS: Patients that met the following criteria were included: 1 to 5 lung-only metastases at the beginning of stereotactic body radiation therapy (SBRT) was performed between January 2004 and June 2015, and the biological effective dose (BED) of SBRT was 75 Gy or more. The parameters included in the analyses were age, gender, ECOG PS, primary lesion, pathology, oligoetastatic state, SBRT date, chemotherapy before SBRT, chemotherapy concurrent SBRT, chemotherapy after SBRT, maximum tumor diameter, number of metastases, field coplanarity, dose prescription, BED10, OTT of SBRT. RESULTS: In total, 1,378 patients with 1,547 tumors were enrolled. Oligo-recurrence occurred in 1,016 patients, sync-oligometastases in 118, and unclassified oligometastases in 121. The three-year OS was 64.0% for oligo-recurrence and 47.5% for sync-oligometastasis (p<0.001). In the multivariate analysis, the hazard ratio (HR) for sync-oligometastases versus oligo-recurrence was 1.601 (p=0.014). Adverse events of Grade 5 were occurred in 3 patients. CONCLUSION: This is the first nationwide to indicate that the OS of patients with pulmonary oligo-recurrence is better than that of patients with sync-oligometastases. Copyright